

# Andrew B Sharabi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8174477/publications.pdf>

Version: 2024-02-01

54  
papers

4,420  
citations

186265  
28  
h-index

182427  
51  
g-index

56  
all docs

56  
docs citations

56  
times ranked

7309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 514-528.	0.8	11
2	Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 616-624.	4.1	20
3	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. , 2022, 235, 108114.		13
4	Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data. <i>Clinical Cancer Research</i> , 2022, 28, 1832-1840.	7.0	7
5	Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. <i>Cancer</i> , 2022, 128, 1948-1957.	4.1	3
6	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. <i>Nature Communications</i> , 2022, 13, .	12.8	14
7	Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 396-412.	0.8	37
8	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	4.1	33
9	Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature. <i>Frontiers in Oncology</i> , 2021, 11, 662954.	2.8	17
10	Scirrhou carcinoma: A previously undescribed tumor of the oral cavity. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03864.	0.5	0
11	Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. <i>Clinical Cancer Research</i> , 2021, 27, 6075-6082.	7.0	40
12	End of treatment cone-beam computed tomography (CBCT) is predictive of radiation response and overall survival in oropharyngeal squamous cell carcinoma. <i>Radiation Oncology</i> , 2021, 16, 147.	2.7	2
13	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 738626.	2.8	9
14	Split course palliative radiotherapy for advanced lung cancer with 3D planning based analysis of outcome: a retrospective review. <i>Annals of Palliative Medicine</i> , 2021, .	1.2	1
15	Hypofractionated radiation therapy as palliative management for symptomatic and local control of advanced thoracic malignancies. <i>Annals of Palliative Medicine</i> , 2021, 10, 10360-10368.	1.2	2
16	Adaptive replanning using cone beam CT for deformation of original CT simulation. <i>Journal of Medical Radiation Sciences</i> , 2021, , .	1.5	3
17	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	2.2	39
18	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. <i>Nature Communications</i> , 2020, 11, 4965.	12.8	172

#	ARTICLE	IF	CITATIONS
19	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2139-2145.	4.1	50
20	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	7.0	117
21	Macrophage Syk-PI3K <sup>3</sup> Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 755-764.	4.1	24
22	Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation. <i>Clinical Cancer Research</i> , 2020, 26, 2693-2703.	7.0	52
23	HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. <i>Cancer Research</i> , 2020, 80, 732-746.	0.9	36
24	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	4.8	23
25	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	7.0	85
26	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546.	12.8	98
27	TNF± and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. <i>Cancer Immunology Research</i> , 2018, 6, 422-433.	3.4	59
28	Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 478-485.	0.8	14
29	Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. <i>JAMA Oncology</i> , 2018, 4, 120.	7.1	21
30	Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. <i>Annals of Thoracic Surgery</i> , 2018, 105, 425-431.	1.3	60
31	Development of Care Pathways to Standardize and Optimally Integrate Multidisciplinary Care for Head and Neck Cancer. <i>Oncology Issues</i> , 2018, 33, 28-44.	0.1	6
32	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	2.8	18
33	Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 5058-5071.	7.0	213
34	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. <i>Oncologist</i> , 2017, 22, 631-637.	3.7	91
35	Immunotherapy and radiation in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 531-539.	2.9	29
36	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	7.0	704

#	ARTICLE	IF	CITATIONS
37	Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review. PLoS ONE, 2016, 11, e0156489.	2.5	5
38	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30
39	A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients. Medical Physics, 2015, 42, 4329-4337.	3.0	37
40	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunology Research, 2015, 3, 345-355.	3.4	520
41	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology, The, 2015, 16, e498-e509.	10.7	660
42	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. , 2014, 2, 14.		108
43	Current standards and future directions for prostate cancer radiation therapy. Expert Review of Anticancer Therapy, 2013, 13, 75-88.	2.4	13
44	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 369-379.	0.7	3
45	Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. Journal of Gastrointestinal Oncology, 2013, 4, 343-51.	1.4	55
46	Enhanced Generation of Myeloid Lineages in Hematopoietic Differentiation from Embryonic Stem Cells by Silencing Transcriptional Repressor Twist-2. Cloning and Stem Cells, 2009, 11, 523-533.	2.6	5
47	Embryonic Stem Cells and Mammary Luminal Progenitors Directly Sense and Respond to Microbial Products. Stem Cells, 2009, 27, 1604-1615.	3.2	28
48	Twist-2 Controls Myeloid Lineage Development and Function. PLoS Biology, 2008, 6, e316.	5.6	65
49	Membrane-type Matrix Metalloproteinase-1 (MT1-MMP) Is a Processing Enzyme for Human Laminin $\beta$ 2 Chain. Journal of Biological Chemistry, 2005, 280, 88-93.	3.4	116
50	Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB Journal, 2004, 18, 1-22.	0.5	70
51	Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. Journal of Cell Science, 2004, 117, 1319-1328.	2.0	314
52	Matrix metalloproteinases process the laminin-5 $\beta$ 2-chain and regulate epithelial cell migration. Biochemical and Biophysical Research Communications, 2003, 303, 1012-1017.	2.1	91
53	Discrete Proteolysis of Focal Contact and Adherens Junction Components in Porphyromonas gingivalis- Infected Oral Keratinocytes: a Strategy for Cell Adhesion and Migration Disabling. Infection and Immunity, 2002, 70, 5846-5856.	2.2	72
54	Inhibitory Role of $\beta$ 4-Associated ErbB-2 and Phosphoinositide 3-Kinase in Keratinocyte Haptotactic Migration Dependent on $\beta$ 1 Integrin. Journal of Cell Biology, 2001, 153, 465-478.	5.2	105